BioSpace News Archive

Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, is furthering its mission to advance the next generation of high parameter cell analysis by continuing to have an active presence at key industry events worldwide.

Tivic Health® Systems, Inc. announced that it has received notice from The NASDAQ Stock Market LLC informing Tivic that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The NASDAQ Capital Market and that it is in compliance with all applicable listing standards.

RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX™ biology-guided radiotherapy.

De La Vina Surgicenter in Santa Barbara, CA, and medical device and technology company Lazurite® announced that De La Vina is the first healthcare center in Southern California to adopt Lazurite’s new ArthroFree® Wireless Surgical Camera System.

The Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe.

The Menarini Group and Stemline Therapeutics Inc. announced that the European Commission has approved ORSERDU® as a monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor ‑positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.

Hepagene Therapeutics, Inc. a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its HPG7233.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties.

Vyant Bio, Inc., announced that its special meeting of stockholders on September 20, 2023 was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023.

Predicine, Inc., a pioneer in the field of liquid biopsy, announced a new study published in The New England Journal of Medicine, demonstrating the clinical utility of its minimal residual disease Liquid Biopsy Assay in support of Genentech’s Phase 1 Clinical Trial of Divarasib.